Page 1

aTyr aTyr Pharma Announces Second Quarter 2026 Results , Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD August 7 , 2026 Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis . Workforce reduction of approximately 60 % and program prioritization conserves capital and aligns resources on efzofitimod program in ILD . Enrollment completed in Phase 2 EFZO - CONNECT ™ study of efzofitimod in SSC - ILD ; topline results expected in the first quarter of 2027 . Ended the second quarter 2026 with $ 58.9 million in cash , cash equivalents , restricted cash and investments ; cash runway into late 2028 based on current operations . SAN DIEGO , Aug. 07 , 2026 ( GLOBE NEWSWIRE ) -- aTyr Pharma , Inc. ( Nasdaq : ATYR ) ( " aTyr " or the " Company " ) , a clinical stage biotechnology company engaged in the discovery and development of first - in - class medicines from its proprietary tRNA synthetase platform , today announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease ( ILD ) , including pulmonary sarcoidosis and systemic sclerosis ( SSC ) -related ILD ( SSC - ILD ) . The program prioritization aims to focus the Company's resources on advancing its lead asset , efzofitimod , and targeted pipeline development to conserve capital in anticipation of receiving comments from the U.S. Food and Drug Administration ( FDA ) on the protocol for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis , a major form of ILD . The Company submitted the protocol in June 2026 and is expecting feedback from the FDA by the end of August 2026 . " We are proactively taking decisive , necessary action to focus our resources on our lead therapeutic candidate , efzofitimod , as we await feedback from the FDA on the protocol we submitted for our planned Phase 3 study in pulmonary sarcoidosis patients with restrictive lung disease . This approach positions aTyr to advance this planned Phase 3 study efficiently and continue completing the Phase 2 EFZO - CONNECTTM study in SSC - ILD , " said Sanjay S. Shukla , M.D. , M.S. , President and Chief Executive Officer of aTyr . " We remain confident in the potential of efzofitimod to become a meaningful therapy for patients with these forms of ILD , and these changes are essential to our ability to achieve that goal . We are deeply grateful to our dedicated team members for their outstanding contributions , commitment , and perseverance , including those who have helped advance tRNA synthetase biology over the years . " Program Prioritization and Corporate Restructuring • Workforce reduction of approximately 60 % will align organizational resources to support the efzofitimod program in ILD in anticipation of comments from the FDA on a protocol submitted for a planned Phase 3 study in pulmonary sarcoidosis and to complete the Phase 2 EFZO - CONNECT ™ study in SSC - ILD . • Jill Broadfoot , aTyr's Chief Financial Officer ( CFO ) , will step down as of September 30 , 2026 , and transition to serve as a consultant to the Company . Brandon Yaras , aTyr's Vice President of Finance , will be appointed as CFO as of October 1 , 2026 . • Nancy Denyes , aTyr's General Counsel , will step down as of September 30 , 2026 , and transition to serve as a consultant to the Company . • The Company expects that this restructuring and additional cost saving measures will reduce annualized operating expenses by approximately $ 13 million , beginning in the fourth quarter of 2026 . Second Quarter 2026 and Subsequent Period Highlights • Protocol submitted to FDA in June 2026 for planned Phase 3 study in patients with chronic , symptomatic pulmonary sarcoidosis with restrictive lung disease . The Company is expecting feedback from the FDA by the end of August 2026. The Phase 3 trial is expected to be a global , randomized , double - blind , placebo - controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis . The 54 - week study will consist of two parallel cohorts randomized equally to either 5.0 mg / kg efzofitimod or placebo dosed intravenously once every 3 weeks for a total of 17 doses . The study is intended to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis with restrictive lung disease who are receiving a stable dose of ≤ 5.0 mg daily oral corticosteroid and / or a background immunosuppressant . All background treatment will remain stable throughout the duration of the study . The primary endpoint of the study will be change from baseline in forced vital capacity ( FVC ) at week 48 and the key secondary endpoint will be change from baseline in the King's Sarcoidosis Questionnaire - Lung score at week 48 .